Glycoxidative stress and cardiovascular complications in experimentally- induced diabetes: Effects of antioxidant treatment

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 2, 2010, Pages 240-256

  Karasu, Çimen ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Cardiovascular; Diabetes mellitus; Glycation; Glycoxidative stress

Indexed keywords

1 METHYLNICOTINAMIDE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CHROMIUM PICOLINATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; FREE RADICAL; ICOSANOID; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOL; RETINOL ACETATE; STOBADINE; SUPEROXIDE; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; AUTOOXIDATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DISRUPTION; CELL FUNCTION; DEFENSE MECHANISM; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXPERIMENTAL MODEL; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART MUSCLE CONTRACTILITY; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MICROANGIOPATHY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TISSUE INJURY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84855509329     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010240     Document Type: Review

References (224)

1. Amos A, McCarthy D, Zimmet P. The rising global burden ofdiabetes and its complications: estimates and projections to the year2010. Diabet Med 1997; 14: S1-S85.
2. Howard BV, Magee MF. Diabetes and cardiovascular disease. CurrAtheroscler Rep 2000; 2: 476-81.
3. Brownlee M. Biochemistry and molecular biology of diabetic complications. Nature 2001; 414: 813-20.
4. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?Metabolism 1995; 44: 363-8.
5. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidativestress and stress-activated signalling pathways: a unifying hypothesisof type 2 diabetes. Endocr Rev 2002; 23: 599-622.
6. Goh SY, Cooper ME. Clinical review: The role of advanced glycationend products in progression and complications of diabetes. JClin Endocrinol Metab 2008; 93: 1143-52.
7. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-OtínM. Hyperglycemia and glycation in diabetic complications. AntioxidRedox Signal 2009; 11: 3071-109.
8. Vanhoutte PM. Endothelial dysfunction and vascular pathology. Bull Mem Acad R Med Belg 2006; 161: 529-36.
9. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutictargets. Curr Med Chem 2009; 16: 94-112.
10. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008; 45: 1-16.
11. Jakus V. The role of free radicals, oxidative stress and antioxidantsystems in diabetic vascular disease. Bratisl Lek Listy 2000; 101:541-51.
12. Yan SF, Ramasamy R, Schmidt AM. The receptor for advancedglycation endproducts (RAGE) and cardiovascular disease. ExpertRev Mol Med 2009; 11: e9.
13. Yamagishi S. Advanced glycation end products and receptoroxidativestress system in diabetic vascular complications. TherApher Dial 2009; 13: 534-9.
14. Bell DS. Heart failure: the frequent, forgotten, and often fatal complicationof diabetes. Diabetes Care 2003; 26: 2433-41.
15. Ahmed SS, Jakeri GA, Narang RM, Regan TJ. Preclinical abnormalityof left ventricular function in diabetes mellitus. Am Heart J1975; 89: 153-58.
16. Fumelli P, Romagnoli F, Carlino G, Fumelli C, Boemi M. Diabetesmellitus and chronic heart failure. Arch Gerontol Geriatr 1996; 23:277-81.
17. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. CardiovascDrugs Ther 1994; 8: 65-73.
18. Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci 2009; 116: 741-60.
19. Karasu C, Oztürk Y, Altan N, Yildizoglu-Ari N, Ikizler C, AltanVM. Thyroid hormones mediated effect of insulin on alloxan diabeticrat atria. Gen Pharmacol 1990; 21: 735-40.
20. Öztürk Y, Yildizoglu-Ari N, Altan VM, Özçelikay AT. Effect ofinsulin on the decreased b-adrenergic responses of duodenum andatrium isolated from streptozotocin diabetic rats. Gen Pharmacol1993; 24: 217-23.
21. Özüari A, Öztürk Y, Yldizoglu-Ari N, Özçelikay AT, Altan VM. The effects of glyburide and insulin on the cardiac performance inrats with non-insulin dependent diabetes mellitus. Gen Pharmacol1993; 24: 165-9
22. Ceylan-Isik A, Hünkar T, Asan E, et al. (Antioxidants in Diabetes-Induced Complications) The ADIC Study Group. Cod liver oilsupplementation improves cardiovascular and metabolic abnormalitiesin streptozotocin diabetic rats. J Pharm Pharmacol 2007;59: 1629-41.
23. Nemoto O, Kawaguchi M, Yaoita H, Miyake K, Maehara K, MaruyamaY. Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ J 2006; 70: 327-34.
24. Borges GR, de Oliveira M, Salgado HC, Fazan R Jr. Myocardialperformance in conscious streptozotocin diabetic rats. CardiovascDiabetol 2006; 5: 26.
25. Bilginoglu A, Cicek FA, Ugur M, Gurdal H, Turan B. The role ofgender differences in beta-adrenergic receptor responsiveness ofdiabetic rat heart. Mol Cell Biochem 2007; 305: 63-9.
26. Huisamen B, Marais E, Genade S, Lochner A. Serial changes in themyocardial beta-adrenergic signalling system in two models ofnon-insulin dependent diabetes mellitus. Mol Cell Biochem 2001;219: 73-82.
27. Kim SK, Zhao ZS, Lee YJ, et al. Left-ventricular diastolic dysfunctionmay be prevented by chronic treatment with PPAR-alpha or-gamma agonists in a type 2 diabetic animal model. Diabetes MetabRes Rev 2003; 19: 487-93.
28. Gando S. Pharmacological studies on alterations in myocardialbeta-adrenoceptors and their intracellular signal transduction in experimentaldiabetic rats. Hokkaido Igaku Zasshi 1994; 69: 1140-53.
29. Dinçer UD, Bidasee KR, Güner S, Tay A, Ozçelikay AT, AltanVM. The effect of diabetes on expression of beta1-, beta2-, andbeta3-adrenoreceptors in rat hearts. 1: Diabetes 2001; 50: 455-61.
30. Wichelhaus A, Russ M, Petersen S, Eckel J. G protein expressionand adenylate cyclase regulation in ventricular cardiomyocytesfrom STZ-diabetic rats. Am J Physiol 1994; 267: H548-55.
31. Gando S, Hattori Y, Kanno M. Altered cardiac adrenergic neurotransmissionin streptozotocin-induced diabetic rats. Br J Pharmacol1993; 109: 1276-81.
32. Kamata K, Satoh T, Tanaka H, Shigenobu K. Changes in electrophysiologicaland mechanical responses of the rat papillary muscleto alpha-and beta-agonist in streptozotocin-induced diabetes. Can JPhysiol Pharmacol 1997; 75: 781-8.
33. Lafçi-Erol D, Altan VM, Oztürk Y. Increased alpha 1-adrenergicresponsiveness of alloxan diabetic rat atria: effects of insulin therapyand thyroidectomy. Gen Pharmacol 1994; 25: 559-64.
34. Tanaka Y, Kashiwagi A, Saeki Y, Shigeta Y. Abnormalities incardiac alpha 1-adrenoceptor and its signal transduction in streptozocin-induced diabetic rats. Am J Physiol 1992; 263: E425-9.
35. Carrier GO, Aronstam RS. Altered muscarinic receptor propertiesand function in the heart in diabetes. J Pharmacol Exp Ther 1987;242: 531-5.
36. Liu TP, Juang SW, Cheng JT, Tong YC. The role of sorbitol pathwayand treatment effect of aldose reductase inhibitor ONO2235 inthe up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats. Neurosci Lett 2005; 383: 131-5.
37. 2-muscarinic receptor gene expression in type-1but not in type-2 diabetic rats. Neurosci Lett 2008; 441: 201-4.
38. Aronstam RS, Carrier GO. Insulin prevention of altered muscarinicreceptor-G protein coupling in diabetic rat atria. Diabetes 1989; 38:1611-6.
39. Cox BF, Clark KL, Perrone MH, et al. Cardiovascular and metaboliceffects of adenosine A1-receptor agonists in streptozotocintreatedrats. J Cardiovasc Pharmacol 1997; 29: 417-26.
40. Grdeñ M, Podgórska M, Szutowicz A, Paweczyk T. Altered expressionof adenosine receptors in heart of diabetic rat. J PhysiolPharmacol 2005; 56: 587-97.
41. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1and its receptors. J Mol Cell Cardiol 2000; 32: 1621-9.
42. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascularsmooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol 2008; 6: 195-203.
43. Stratmann B, Stork I, Tschoepe D. Diabetic cardiomyopathy--atype of coronary artery disease? Internist (Berl). 2008; 49: 436-40.
44. 2+-ATPase activity contributes to cardiacdysfunction in streptozotocin-induced diabetic rats. PhysiolBiochem 2006; 62: 1-8.
45. 2+currentin diabetic rat cardiomyocytes. Am J Physiol 1998; 274: H1849-57.
46. 2+-ATPase activity inheart and liver of streptozotocin-diabetic rats: comparison with vitaminE. Biochim Biophys Acta 2002; 1588: 71-8.
47. 2+and NO. Am J Physiol 1998; 275: H823-30.
48. Ligeti L, Szenczi O, Prestia CM, et al. Altered calcium handling isan early sign of streptozotocin-induced diabetic cardiomyopathy. IntJ Mol Med 2006; 17: 1035-43.
49. Smith JM, Sondgeroth KB, Wahler GM. Inhibition of nitric oxidesynthase enhances contractile response of ventricular myocytesfrom streptozotocin-diabetic rats. Mol Cell Biochem 2007; 300:129-37.
50. Higuchi M, Ikema S, Sakanashi M. Correlation of contractile dysfunctionand abnormal tissue energy metabolism during hypoperfusionwith norepinephrine in isolated rat hearts: differences betweennormal and diabetic hearts. J Mol Cell Cardiol 1992; 24: 1125-41.
51. Feuvray D, Darmellah A. Diabetes-related metabolic perturbationsin cardiac myocyte. Diabetes Metab 2008; 34 Suppl 1: S3-9.
52. Wilson PW. Diabetes mellitus and coronary heart disease. Am JKidney Dis 1998; 32: S89-100.
53. Ding H, Triggle CR. Endothelial cell dysfunction and the vascularcomplications associated with type 2 diabetes: assessing the healthof the endothelium. Vasc Health Risk Manage 2005; 1: 55-71.
54. 2+distribution. Diabetes 1999; 48:1323-30.
55. Pfaffman MA, Ball CR, Darby A, Hilman R. Incsulin reversal ofdiabetes-induced inhibition of vascular contractility in the rat. Am JPhysiol 1982; 242: H490-95.
56. Head PJ, Longhurst PA, Panek RL, Stitzel RE. A contrasting effectof the diabetic state upon the contractile responses of aortic preparationsfrom therat and rabbit. Br J Pharmacol 1987; 91: 275-86.
57. Reyes-Toso CF, Rosón MI, Albornoz LE, Damiano PF, LinaresLM, Cardinali DP. Vascular reactivity in diabetic rats: effect ofmelatonin. J Pineal Res 2002; 33: 81-6.
58. Owen MP, Carrier GO. Alteration in vascular smooth muscle sensitivityto vasoconstrictor agents by streptozotocin induced diabetes. Proc West Pharmacol Soc 1979; 22: 363-66.
59. Harris KH, MacLeod KM. Infuence of the endothelium on contractileresponses of arteries from diabetic rats. Eur J Pharmacol 1988;153: 55-64.
60. Altan VM, Karasu C, Ozüari A. The effects of type-1 and type-2diabetes on endothelium-dependent relaxation in rat aorta. PharmacolBiochem Behav 1989; 33: 519-22.
61. Karasu Ç, Altan VM. The role of endothelial cells on the alterationsin vascular reactivity induced by insulin-dependent diabetesmellitus: Effects of insulin treatment. Gen Pharmacol 1993; 24:743-57.
62. Karasu C, Altan VM. The role of the endothelium on enhancedcontractile response of non-insulin-dependent diabetic rat aortae:effects of insulin treatment. Gen Pharmacol 1994; 25: 795-802.
63. Karasu C, Ozansoy G, Bozkurt O, Erdogan D, Omeroglu S. Antioxidantand triglyceride-lowering effects of vitamin E associatedwith the prevention of abnormalities in the reactivity and morphologyof aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Metabolism1997; 46: 872-9.
64. Koçak G, Aktan F, Canbolat O, et al. ADIC Study Group--Antioxidants in Diabetes-Induced Complications. Alpha-lipoic acidtreatment ameliorates metabolic parameters, blood pressure, vascularreactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr Metab 2000; 13: 308-18.
65. Abboud K, Bassila JC, Ghali-El-Ghoul R, Sabra R. Temporalchanges in vascular reactivity in early diabetes mellitus in rats: roleof changes in endothelial factors and in phosphodiesterase acitvity. Am J Physiol Heart Circ Physiol 2009; 297: H836-45.
66. Zhu BH, Guan YY, Min J, He H. Contractile responses of diabeticrat aorta to phenylephrine at different stages of diabetic duration. Acta Pharmacol Sin 2001; 22: 445-9.
67. Karasu C, Soncul H, Altan VM. Effects of non-insulin dependentdiabetes mellitus on the reactivity of human internal mammary arteryand human saphenous vein. Life Sci 1995; 57: 103-12.
68. Karasu C. Acute probucol treatment partially restores vasomotoractivity and abnormal lipid metabolism whereas morphologicalchanges are not affected in aorta from long-term STZ-diabetic rats. Exp Clin Endocrinol Diabetes 1998; 106: 189-96.
69. Ceylan A, Karasu C, Ari N, Stefek M. Stobadine regulates vascularreactivity and blood pressure via the effects on calcium channelsin chronically diabetic rat aorta. 12th International Congress onCardiovascular Pharmacotherapy; Vascular Biology Section, May7-10, 2003; P15
70. 2+mobilization in aortic smooth musclecells from streptozotocin-induced diabetic rats. Clin Exp PharmacolPhysiol 2008; 35: 568-73.
71. Kamata K, Miyata N, Kasuya Y. Functional changes in potassiumchannels in aortas from rats with streptozotocin-induced diabetes. Eur J Pharmacol 1989; 166: 319-23.
72. Irat AM, Aslamaci S, Karasu C, Ari N. Alteration of vascular reactivityin diabetic human mammary artery and the effects of thiazolidinediones. J Pharm Pharmacol 2006; 58: 1647-53.
73. Yöntem O, Sahilli M, Karasu C, Ozçelikay AT, Altan VM, Ari N. Troglitazone has no effect on K(ATP) channel opener inducedrelaxationsin rat aorta and in human saphenous veins from patientswith type 2 diabetes. Life Sci 2000; 68: 557-68.
74. Furchgott RF, Zawadzki JV. The obligatory role of endothelialcells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
75. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derivedrelaxing factor from pulmonary artery and vein possesses pharmacologicand chemical properties identical to those of nitric oxideradical. Circ Res 1987; 61: 866-79.
76. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accountsfor the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
77. Palmer RM, Ashton DS, Moncada S. Vascular endothelialcells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-6.
78. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylatecyclase by sodium nitroprusside, nitroglycerin and nitric oxide invarious tissue preparations and comparison to the effects of sodiumazide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3: 23-35.
79. Koshland DE Jr. The molecule of the year. Science 1992; 258:1861.
80. 2+-dependently converts L-arginine intoan activator of soluble guanylyl cyclase. Biochem Biophys ResCommun 1989; 164: 678-85.
81. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur JPharmacol 1986; 132: 75-8.
82. Durante W, Sen AK, Sunahara FA. Impairment of endotheliumdependentrelaxation in aortae from spontaneously diabetic rats. BrJ Pharmacol 1988; 94: 463-8.
83. Taylor PD, McCarthy AL, Thomas CR, Poston L. Endotheliumdependentrelaxation and noradrenaline sensitivity in mesentericresistance arteries of streptozotocin-induced diabetic rats. Br JPharmacol 1992; 107: 393-9.
84. Pieper GM, Mei DA, Langenstroer P, O'Rourke ST. Bioassay ofendothelium-derived relaxing factor in diabetic rat aorta. Am JPhysiol 1992; 263: H676-80.
85. Pieper GM. Review of alterations in endothelial nitric oxide productionin diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31: 1047-60.
86. Abiru T, Watanabe Y, Kamata K, Miyata N, Kasuya Y. Decreasein endothelium-dependent relaxation and levels of cyclic nucleotidesin aorta from rabbits with alloxan-induced diabetes. ResCommun Chem Pathol Pharmacol 1990; 68: 13-25
87. Mulhern M, Docherty JR. Effects of experimental diabetes on theresponsiveness of rat aorta. Br J Pharmacol 1989; 97: 1007-12
88. Pieper, G.M. Enhanced, unaltered and impaired nitric oxidemediatedendothelium-dependent relaxation in experimental diabetesmellitus: importance of disease duration. Diabetologia 1999; 42:204-13.
89. 2+stores. Circ Res 1999; 84: 201-9.
90. 2+influx. Circ Res1999; 84: 210-9
91. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium:History and impact on cardiovascular disease. Vasc Pharmacol2006; 45: 268-76.
92. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, VanhouttePM. Endothelial dysfunction in diabetes. Br J Pharmacol2000; 130: 963-74.
93. Félétou M, Vanhoutte PM. EDHF: new therapeutic targets? PharmacolRes 2004; 49: 565-80.
94. Marczin N, Antonov A, Papapetropoulos A, et al. Monocyteinduceddownregulation of nitric oxide synthase in cultured aorticendothelial cells. Arterioscler Thromb Vasc Biol 1996; 16: 1095-103.
95. Karasu C, Ozansoy G, Bozkurt O, Erdogan D, Omeroglu S. Changes in isoprenaline-induced endothelium-dependent and-independent relaxations of aorta in long-term STZ-diabetic rats: reversaleffect of dietary vitamin E. Gen Pharmacol 1997; 29: 561-7.
96. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanismunderlying insulin resistance, diabetes, and cardiovascular disease?The common soil hypothesis revisited. Arterioscler Thromb VascBiol 2004; 24: 816-23.
97. Chatterjee A, Catravas JD. Endothelial nitric oxide (NO) and itspathophysiologic regulation. Vasc Pharmacol 2008; 49: 134-40.
98. Chang KC, Chung SY, Chong WS, et al. Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 1993; 266: 992-1000.
99. Heinzel B, John M, Klatt P, Böhme E, Mayer B. Ca2+/calmodulindependentformation of hydrogen peroxide by brain nitric oxidesynthase. Biochem J 1992; 281: 627-30.
100. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabeticvascular complications. Diabetes Care1996; 19: 257-67.
101. Maritim AC, Sanders RA, Watkins JB 3rd: Diabetes, oxidativestress, and antioxidants: A review. J Biochem Mol Toxicol 2003;17: 24-38.
102. Turko IV, Marcondes S, Murad F: Diabetes-associated nitration oftyrosine and inactivation of succinyl-CoA: 3-oxoacid CoA transferase. Am J Physiol Heart Circ Physiol 2001; 281: H2289-94
103. Piconi L, Quagliaro L, Ceriello A Oxidative stress in diabetes. ClinChem Lab Med 2003; 41: 1144-9.
104. Jakus V, Rietbrock N. Advanced glycation end-products and theprogress of diabetic vascular complications. Physiol Res 2004; 53:131-42.
105. Ceriello A. Hyperglycaemia: the bridge between non-enzymaticglycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 1999; 12: 42-6.
106. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones 2008; 7: 123-32.
107. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 suppresses cell oxidant stress and activationsignaling via EGF receptor. Proc Natl Acad Sci USA 2006;103: 13801-6.
108. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA. Roleof oxidative stress in development of cardiovascular complicationsin diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-27
109. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increasedvascular superoxide production in human diabetes mellitus: role ofNAD(P)H oxidase and endothelial nitric oxide synthase. Circulation2002; 105: 1656-62
110. Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E. Novel approaches to improving endotheliumdependentnitric oxide-mediated vasodilatation. Pharmacol Rep2009; 61: 105-15.
111. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress andthe use of antioxidants in diabetes: linking basic science to clinicalpractice. Cardiovasc Diabetol 2005; 4: 5.
112. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes:a double-edged sword in redox signalling. Cardiovasc Res2009; 82: 9-20
113. Ding H, Hashem M, Triggle C. Increased oxidative stress in thestreptozotocin-induced diabetic apoE-deficient mouse: changes inexpression of NADPH oxidase subunits and eNOS. Eur J Pharmacol2007; 561: 121-8.
114. Karasu C. Time course of changes in endothelium-dependent and-independent relaxation of chronically diabetic aorta: role of reactiveoxygen species. Eur J Pharmacol 2000; 392: 163-73.
115. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutaserecovers altered endothelium-dependent relaxation in diabetic rataorta. Am J Physiol 1991; 261: H1086-94.
116. Cohen RA. The role of nitric oxide and other endothelium-derivedvasoactive substances in vascular disease. Prog Cardiovasc Dis1995; 38: 105-28.
117. Kamata K, Kobayashi T. Changes in superoxide dismutase mRNAexpression by streptozotocin-induced diabetes. Br J Pharmacol1996; 119: 583-9.
118. 2in aorta isolated from chronicallystreptozotocin-diabetic rats: effects of antioxidant enzymesand enzymes inhibitors. Free Radic Biol Med 1999; 27: 16-27.
119. 2by alpha-lipoic acidmediates the recovery of basal EDRF/NO availability and thereversal of superoxide dismutase-induced relaxation in diabetic rataorta. Diabetes Obes Metab 2002; 4: 69-74.
120. Matoba, T, Shimokawa H, Nakashima M, et al. Hydrogen peroxideis an endothelium-derived hyperpolarizing factor in mice. J ClinInvest 2000; 106: 1521-30.
121. Pieper GM, Gross GJ. Oxygen free radicals abolish endotheliumdependentrelaxation in diabetic rat aorta. Am J Physiol 1988; 255:H825-33.
122. Tesfamariam B, Cohen RA. Free radicals mediate endothelial celldysfunction caused by elevated glucose. Am J Physiol 1992; 263:H321-6.
123. Pieper GM, Siebeneich W, Roza AM, Jordan M, Adams MB. Chronic treatment in vivo with dimethylthiourea, a hydroxyl radicalscavenger, prevents diabetes-induced endothelial dysfunction. JCardiovasc Pharmacol 1996; 28: 741-5
124. Vanhoutte PM. Endothelium-derived free radicals: for worse andfor beter. J Clin Invest 2001; 107: 23-25.
125. 2+and other cellular metabolites. Gen Pharmacol 1999; 33:325-36.
126. Chun TH, Itoh H, Saito T, et al. Oxidative stress augments secretionof endothelium-derived relaxing peptides, C-type natriureticpeptide and adrenomedulin. J Hyperten 2000; 18: 575-80.
127. Kobayashi T, Kamata K. Effect of chronic insulin treatment on NOproduction and endothelium-dependent relaxation in aortae fromestablished STZ-induced diabetic rats. Atherosclerosis 2001; 155:313-20.
128. Ceriello A. Nitrotyrosine: new findings as a marker of postprandialoxidative stress. Int J Clin Pract Suppl 2002; 129: 51-8.
129. Szabo C. Role of nitrosative stress in the pathogenesis of diabeticvascular dysfunction. Br J Pharmacol 2009; 156: 713-27
130. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelialdysfunction in diabetes mellitus. Endothelium 2004; 11: 89-97.
131. Zobali F, Cakici I, Karasu C. Effects of peroxynitrite on thereactivity of diabetic rat aorta. Pharmacology 2001; 63: 58-64.
132. Sowers JR. Hypertension, angiotensin II, and oxidative stress. NEngl J Med 2002; 346: 1999-2001.
133. Crespo MJ, Moreta S, González J. Cardiovascular deterioration inSTZ-diabetic rats: possible role of vascular RAS. Pharmacology2003; 68: 1-8.
134. Taguchi K, Kobayashi T, Hayashi Y, Matsumoto T, Kamata K. Enalapril improves impairment of SERCA-derived relaxationand enhancement of tyrosine nitration in diabetic rat aorta. Eur JPharmacol 2007; 556: 121-8.
135. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3: 853-76.
136. Hartge MM, Unger T, Kintscher U. The endothelium and vascularinflammation in diabetes. Diab Vasc Dis Res 2007; 4: 84-8.
137. Kamata K, Miyata N, Abiru T, Kasuya Y. Functional changes invascular smooth muscle and endothelium of arteries during diabetesmellitus. Life Sci 1992; 50: 1379-87.
138. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide:mechanisms and therapeutic potential. Cardiovasc Res 2002; 55:250-60.
139. Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctionalarginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995; 25: 397-403
140. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, DosSantos RA, Simões e Silva AC. The renin-angiotensin system anddiabetes: an update. Vasc Health Risk Manage 2008; 4: 787-803.
141. Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E. Novel approaches to improving endotheliumdependentnitric oxide-mediated vasodilatation. Pharmacol Rep2009; 61: 105-15.
142. Ceylan A, Karasu C, Aktan F, Güven C, Can B, Ozansoy G. Effectsof simvastatin treatment on oxidant/antioxidant state and ultrastructureof diabetic rat myocardium. Gen Physiol Biophys2003; 22: 535-47.
143. Ceylan A, Karasu C, Aktan F, Ozansoy G. Simvastatin treatmentrestores vasoconstriction and the inhibitory effect of LPC on endothelialrelaxation via affecting oxidizing metabolism in diabeticrats. Diabetes Nutr Metab 2004; 17: 203-10.
144. Wölkart G, Stessel H, Saad Z, Kirchengast M, BrunnerF. Cardioprotective effects of atrasentan, an endothelin-A receptorantagonist, but not of nitric oxide in diabetic mice with myocytespecificoverexpression of endothelial nitric oxide synthase. Br JPharmacol 2006; 148: 671-81.
145. Bartuoe M, Lomnicka M, Kostogrys RB, et al. 1-Methylnicotinamide(MNA) prevents endothelial dysfunction in hypertriglyceridemicand diabetic rats. Pharmacol Rep 2008; 60: 127-38.
146. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascularinjury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-16.
147. Zobali F, Avci A, Canbolat O, Karasu C. Effects of vitamin A andinsulin on the antioxidative state of diabetic rat heart: a comparisonstudy with combination treatment. Cell Biochem Funct 2002; 20:75-80.
148. Ulusu NN, Sahilli M, Avci A, et al. Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense duringoxidative stress in diabetic rodent brain and peripheral organs: effectsof stobadine and vitamin E. Neurochem Res 2003; 28: 815-23.
149. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targetsfor novel antioxidant strategies. Drug Discov Today 2006; 11: 524-33.
150. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functionaldeficit in diabetic cardiomyopathy. Mol Cell Biochem 1996; 160-61: 283-8.
151. Baluchnejadmojarad T, Roghani M. Chronic administration ofgenistein improves aortic reactivity of streptozotocin-diabetic rats:mode of action. Vascul Pharmacol 2008; 49: 1-5.
152. Heistad DD. Endothelial function in the time of the giants. J CardiovascPharmacol 2008; 52: 385-92.
153. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes:revisiting the controversy. Diabetes Metab 2003; 29: 579-85.
154. Zobali F, Besler T, Ari N, Karasu C. (Antioxidants in Diabetes-Induced Complications) The ADIC Study Group. Hydrogen peroxide-induced inhibition of vasomotor activity: evaluation of singleand combined treatments with vitamin A and insulin in streptozotocin-diabetic rats. Int J Exp Diabetes Res 2002; 3: 119-30.
155. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycationendproduct crosslink breaker (alagebrium) improves endothelialfunction in patients with isolated systolic hypertension. J Hypertens2007; 25: 577-83.
156. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine preventsmacro-and microvascular endothelial dysfunction and oxidativestress following a meal rich in advanced glycation end products inindividuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-71.
157. Moreau R, Nguyen BT, Doneanu CE, Hagen TM. Reversal byaminoguanidine of the age-related increase in glycoxidation andlipoxidation in the cardiovascular system of Fischer 344 rats. BiochemPharmacol 2005; 69: 29-40.
158. Mattson MP. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associatedvascular and neurodegenerative disorders. Exp Gerontol 2009; 44:625-34.
159. Hünkar T, Aktan F, Ceylan A, Karasu C. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Effects of cod liveroil on tissue antioxidant pathways in normal and streptozotocindiabeticrats. Cell Biochem Funct 2002; 20: 297-302.
160. Günes A, Ceylan A, Sarioglu Y, Stefek M, Bauer V, Karasu C. Antioxidants in Diabetes-induced Complications (ADIC) StudyGroup. Reactive oxygen species mediate abnormal contractileresponse to sympathetic nerve stimulation and noradrenaline in thevas deferens of chronically diabetic rats: effects of in vivo treatmentwith antioxidants. Fundam Clin Pharmacol 2005; 19: 73-9
161. Yülek F, Or M, Ozoǧul C, et al. Effects of stobadine and vitamin Ein diabetes-induced retinal abnormalities: involvement of oxidativestress. Arch Med Res 2007; 38: 503-11.
162. Das Evcimen N, Ulusu NN, Karasu C, Doǧru B. Adenosinetriphosphatase activity of streptozotocin-induced diabetic rat brainmicrosomes: Effect of vitamin E. Gen Physiol Biophys 2004; 23:347-55.
163. 2+-ATPase activity andcalcium levels in streptozotocin-induced diabetic rat kidney. CellBiochem Funct 2003; 21: 177-82.
164. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR. Effects of antioxidanttreatment on sciatic nerve dysfunction in streptozotocindiabeticrats; comparison with essential fatty acids. Diabetologia1995; 38: 129-34.
165. Skalska S, Kyselova Z, Gajdosikova A, Karasu C, Stefek M, StolcS. Protective effect of stobadine on NCV in streptozotocin-diabeticrats: augmentation by vitamin E. Gen Physiol Biophys 2008; 27:106-14.
166. Keegan A, Walbank H, Cotter MA, Cameron NE. Chronic vitaminE treatment prevents defective endothelium-dependent relaxation indiabetic rat aorta. Diabetologia 1995; 38: 1475-8.
167. Hamblin M, Smith HM, Hill MF. Dietary supplementation withvitamin E ameliorates cardiac failure in type I diabetic cardiomyopathyby suppressing myocardial generation of 8-isoprostaglandinF2alpha and oxidized glutathione. J Card Fail 2007;13: 884-92.
168. Peerapatdit T, Patchanans N, Likidlilid A, Poldee S, Sriratanasathavorn C. Plasma lipid peroxidation and antioxidiantnutrients in type 2 diabetic patients. J Med Assoc Thai 2006; 89(5):S147-55.
169. Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT. Vitamin Esupplementation improves endothelial function in type I diabetesmellitus: a randomized, placebo-controlled study. J Am Coll Cardiol2000; 36: 94-102.
170. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial functionin Type 1 but not Type 2 diabetes mellitus. Am J Physiol 2003;285: H2392-98.
171. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementationand cardiovascular events in high-risk patients. TheHeart Outcomes Prevention Evaluation Study Investigators. N EnglJ Med 2000; 342: 154-60.
172. Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO TrialInvestigators. Effects of long-term vitamin E supplementation oncardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-47.
173. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effects of vitamins C and E and beta-carotene on the risk of type 2diabetes in women at high risk of cardiovascular disease: a randomizedcontrolled trial. Am J Clin Nutr 2009; 90: 429-37.
174. Srivatsan R, Das S, Gadde R, et al. Antioxidants and lipid peroxidationstatus in diabetic patients with and without complications. Arch Iran Med 2009; 12: 121-7
175. Gutierrez AD, de Serna DG, Robinson I, Schade DS. The responseof gamma vitamin E to varying dosages of alpha vitamin E plus vitaminC. Metabolism 2009; 58: 469-78.
176. Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biologicalantioxidant. Free Radic Biol Med 1995; 19: 227-50.
177. Nohl H, Gille L. Evaluation of the antioxidant capacity of ubiquinoland dihydrolipoic acid. Z Naturforsch C 1998; 53: 250-3.
178. Balkis Budin S, Othman F, Louis SR, et al. Effect of alpha lipoicacid on oxidative stress and vascular wall of diabetic rats. Rom JMorphol Embryol 2009; 50: 23-30.
179. Strödter D, Lehmann E, Lehmann U, Tritschler HJ, Bretzel RG, Federlin K. The influence of thioctic acid on metabolism and functionof the diabetic heart. Diabetes Res Clin Pract 1995; 29: 19-26.
180. Maritim AC, Sanders RA, Watkins JB 3rd. Effects of alpha-lipoicacid on biomarkers of oxidative stress in streptozotocin-induceddiabetic rats. J Nutr Biochem 2003; 14: 288-94
181. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Zeuzem S, Chow KU. Antioxidative treatment prevents activation of death-receptor-andmitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia 2004; 47: 2072-80.
182. Oksala NK, Laaksonen DE, Lappalainen J, et al. Heat shock protein60 response to exercise in diabetes: effects of alpha-lipoic acidsupplementation. J Diabetes Complicat 2006; 20: 257-61.
183. Ziegler D. Thioctic acid for patients with symptomatic diabeticpolyneuropathy: a critical review. Treat Endocrinol 2004; 3: 173-89.
184. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomaticdiabetic peripheral neuropathy with the anti-oxidant alphalipoicacid. A 3-week multicentre randomized controlled trial(ALADIN Study). Diabetologia 1995; 38: 1425-33.
185. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathywith the antioxidant thioctic acid (alpha-lipoic acid): atwo year multicenter randomized double-blind placebo-controlledtrial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999; 31: 171-9.
186. Ziegler D, Hanefeld M, Ruhnau K, et al. Treatment of symptomaticdiabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN IIIStudy). ALADIN III Study Group. Alpha-Lipoic Acid in DiabeticNeuropathy. Diabetes Care 1999; 22: 1296-301
187. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effectsof treatment with the antioxidant alpha-lipoic acid on cardiacautonomic neuropathy in NIDDM patients. A 4-month randomizedcontrolled multicenter trial (DEKAN Study). DeutscheKardiale Autonome Neuropathie. Diabetes Care 1997; 20: 369-73.
188. Ziegler D. Painful diabetic neuropathy: advantage of novel drugsover old drugs? Diabetes Care 2009; 32 (Suppl 2): S414-9.
189. Low PA, Nehrdich D, Novosadova M, O'Brien PC, et al. The sensorysymptoms of diabetic polyneuropathy are improved with {alpha}-Lipoic Acid: The SYDNEY Trial. Diabetes Care 2003; 26:770-6.
190. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment ofsymptomatic diabetic polyneuropathy with the antioxidant alphalipoicacid: a meta-analysis. Diabet Med 2004; 21: 114-21.
191. El-Swefy S, Schaefer EJ, Seman LJ, et al. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesionsin hyperlipidemic-diabetic hamsters. Atherosclerosis 2000; 149:277-86.
192. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, PedersenO. Multifactorial intervention and cardiovascular disease in patientswith Type 2 diabetes. N Engl J Med 2003; 348: 383-93.
193. Belch J, MacCuish A, Campbell I, et al. Prevention of Progressionof Arterial Disease and Diabetes Study Group; Diabetes RegistryGroup; Royal College of Physicians Edinburgh. The prevention ofprogression of arterial disease and diabetes (POPADAD) trial: factorialrandomised placebo controlled trial of aspirin and antioxidantsin patients with diabetes and asymptomatic peripheral arterialdisease. Ann Intern Med 2009; 150: JC1-8.
194. Stirban A. Drugs for the treatment of diabetes complications. Zycose:a new player in the field? Drugs Today (Barc) 2008; 44: 783-96.
195. Tanous D, Hime N, Stocker R. Anti-atherosclerotic and antidiabeticproperties of probucol and related compounds. Redox Rep2008; 13: 48-59.
196. Gorogawa S, Kajimoto Y, Umayahara Y, et al. Probucol preservespancreatic beta-cell function through reduction of oxidative stressin type 2 diabetes. Diabetes Res Clin Pract 2002; 57: 1-10.
197. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatinand gemfibrozil metabolites, but not the parent drugs, are potentantioxidants against lipoprotein oxidation. Atherosclerosis 1998;138: 271-80.
198. Ozansoy G, Akin B, Aktan F, Karasu C. Short-term gemfibroziltreatment reverses lipid profile and peroxidation but does not alterblood glucose and tissue antioxidant enzymes in chronically diabeticrats. Mol Cell Biochem 2001; 216: 59-63.
199. Ozansoy G, Akin FB. Effects of gemfibrozil treatment on vascularreactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol2004; 56: 241-6.
200. Sahilli M, Irat AM, Isik AC, Karasu C, Ozansoy G, Ari N. A lackof synergistic interaction between insulin and pioglitazone onreactivity of rat aorta from chronically high dose insulin-treateddiabetic rats. Gen Physiol Biophys 2007; 26: 48-55.
201. Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y. Dietarytroglitazone decreases oxidative stress in early stage type II diabeticrats. Life Sci 2000; 66: 2043-9.
202. Lida KT, Kawakami Y, Suzuki M, et al. Effect of thiazolidinedionesand metformin on LDL oxidation and aortic endothelium relaxationin diabetic GK rats. Am J Physiol 2003; 284: E1125-30.
203. Horakova L, Stolc S. Antioxidant and pharmacodynamic effects ofpyridoindole stobadine. Gen Pharmacol 1998; 30: 627-38.
204. Stefek M, Krizanova L, Trnkova Z. Oxidative modification ofserum albumin in an experimental glycation model of diabetes mellitusin vitro: effect of the pyridoindole antioxidant stobadine. LifeSci 1999; 65: 1995-7.
205. Stefek M, Gajdosik A, Tribulova N, et al. The pyridoindole antioxidantstobadine attenuates albuminuria, enzymuria, kidney lipidperoxidation and matrix collagen cross-linking in streptozotocininduceddiabetic rats. Methods Find Exp Clin Pharmacol 2002; 24:565-71.
206. Stefek M, Sotnikova R, Okruhlicova L, et al. Effect of dietarysupplementation with the pyridoindole antioxidant stobadine on antioxidantstate and ultrastructure of diabetic rat myocardium. ActaDiabetol 2000; 37: 111-7.
207. Cumaoglu A, Cevik C, Rackova L, Ari N, Karasu C. Effects ofantioxidant stobadine on protein carbonylation, advanced oxidationprotein products and reductive capacity of liver in streptozotocindiabeticrats: role of oxidative/nitrosative stress. Biofactors 2007;30: 171-8.
208. +-ATPase in rats with streptozotocin-induced diabetes.Gen Physiol Biophys 2006; 25: 111-24.
209. Guzy J, Barnová E, Benes L. Stobadine and heart mitochondria. Life Sci 1999; 65: 1935-7.
210. Demiryürek AT, Karasu C, Stefek M, Stolc S. Effect of stobadineon leukocyte free radical generation in streptozotocin-diabetic rats:comparison with vitamin E. Pharmacology 2004; 70: 1-4.
211. Kyselova Z, Gajdosik A, Gajdosikova A, et al. Effect of the pyridoindoleantioxidant stobadine on development of experimentaldiabetic cataract and on lens protein oxidation in rats: comparisonwith vitamin E and BHT. Mol Vis 2005; 11: 56-65.
212. Steenken S, Sundquist AR, Jovanovic SV, Crockett R, Sies H. Antioxidant activity of the pyridoindole stobadine. Pulse radiolyticcharacterization of one-electron-oxidized stobadine and quenchingof singlet molecular oxygen. Chem Res Toxicol 1992; 5: 355-60.
213. Kagan VE, Tsuchiya M, Serbinova E, Packer L, Sies H. Interactionof the pyridoindole stobadine with peroxyl, superoxide and chromanoxylradicals. Biochem Pharmacol 1993; 45: 393-400.
214. Clarke IS, Dzialoszynski T, Sanford SE, Chevendra V, TrevithickJR. Dietary strategies to prevent retinopathy in RCS rats. In: LermanS, Tripathi RC, eds. Ocular toxicology: proceedings of theFirst Congress of the International Society of Ocular Toxicology. New York: Dekker 1989; pp. 395-413.
215. Sotnikova R, Stefek M, Okruhlicova L, et al. Dietary supplementationof the pyridoindole antioxidant stobadine reduces vascular impairmentin streptozotocin-diabetic rats. Methods Find Exp ClinPharmacol 2001; 23: 121-9.
216. Misík V, Ondrias K, Gergel D. Antioxidative properties of cardioactiveagents. Bratisl Lek Listy 1993; 94: 66-70.
217. Stolc S. Pyridoindole stobadine is a nonselective inhibitor of voltage-operated ion channels in rat sensory neurons. Gen Physiol Biophys1994; 13: 259-66.
218. Sotníková R, Okruhlicová L, Noskovic P. Endothelial protectiveeffect of stobadine on ischaemia/reperfusion-induced injury. GenPhysiol Biophys 1998; 17: 253-64.
219. Nosál'ová V, Navarová J, Mihalová D, Sotníková R. Mesentericischemia/reperfusion-induced intestinal and vascular damage:effect of stobadine. Methods Find Exp Clin Pharmacol 2007; 29:39-45.
220. Guz G, Demirogullari B, Ulusu NN, et al. Stobadine protects ratkidney against ischaemia/reperfusion injury. Clin Exp PharmacolPhysiol. 2007; 34: 210-6.
221. Stefek M, Snirc V, Djoubissie PO, et al. Carboxymethylatedpyridoindole antioxidants as aldose reductase inhibitors: synthesis, activity, partitioning, and molecular modeling. Bioorg Med Chem2008; 16: 4908-20.
222. Umit Baǧriaçik E, Uslu K, Yurtçu E, Stefek M, Karasu C. Stobadine inhibits doxorubicin-induced apoptosis through acaspase-9 dependent pathway in P815 mastocytoma cells. Cell BiolInt 2007; 31: 979-84.
223. 2induced oxidativedamage in pancreas-cell lines. Türkiye Klinikleri J Med Sci2008; 29 (Suppl 1): S129.
224. Rackova L, Snirc V, Jung T, Stefek M, Karasu C, Grune T. Metabolism-induced oxidative stress is a mediator of glucose toxicityin HT22 neuronal cells. Free Radic Res 2009; 43: 876-86.